KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Net Cash Flow (2016 - 2025)

Novavax (NVAX) has 16 years of Net Cash Flow data on record, last reported at -$25.6 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 21.54% year-over-year to -$25.6 million; the TTM value through Dec 2025 reached -$295.1 million, down 860.77%, while the annual FY2025 figure was -$295.1 million, 860.77% down from the prior year.
  • Net Cash Flow reached -$25.6 million in Q4 2025 per NVAX's latest filing, down from $13.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.4 billion in Q1 2021 and bottomed at -$703.5 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$19.7 million, with a median of -$58.7 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: soared 1214.82% in 2021, then plummeted 1390.19% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$419.5 million in 2021, then soared by 112.29% to $51.6 million in 2022, then tumbled by 265.77% to -$85.5 million in 2023, then surged by 61.88% to -$32.6 million in 2024, then increased by 21.54% to -$25.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$25.6 million in Q4 2025, $13.7 million in Q3 2025, and -$17.4 million in Q2 2025.